Stocktoria
Vir Biotechnology, Inc. VIR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-10-11
Vir Biotechnology, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -699.2% | -791.3% | -794.0% | 51.6% | 38.4% |
| Net margin | -638.9% | -703.4% | -713.7% | 31.9% | 48.3% |
| FCF margin | -578.5% | -611.4% | -928.7% | 98.7% | -6.3% |
| Return on assets | -43.7% | -37.3% | -32.1% | 18.4% | 27.0% |
| Return on equity | -57.2% | -45.4% | -38.7% | 24.8% | 36.9% |
| Current ratio | 5.54 | 8.71 | 9.05 | 4.93 | 4.58 |
| Revenue growth | -7.6% | -13.9% | -94.7% | 47.5% | 1334.4% |
Source: SEC EDGAR filings · CIK 0001706431 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.